A share price of Plus Therapeutics Inc [PSTV] is currently trading at $0.68, down -3.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The PSTV shares have lost -8.90% over the last week, with a monthly amount glided 59.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Plus Therapeutics Inc [NASDAQ: PSTV] stock has seen the most recent analyst activity on September 03, 2025, when D. Boral Capital upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, D. Boral Capital started tracking the stock with Buy rating on March 17, 2025, and set its price target to $9. On January 25, 2021, Ladenburg Thalmann initiated with a Buy rating and assigned a price target of $8 on the stock. Maxim Group started tracking the stock assigning a Buy rating and suggested a price target of $6 on October 16, 2020.
Plus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.16 and $2.31. Plus Therapeutics Inc [NASDAQ: PSTV] shares were valued at $0.68 at the most recent close of the market.
Analyzing the PSTV fundamentals
Trailing Twelve Months sales for Plus Therapeutics Inc [NASDAQ:PSTV] were 5.32M which represents 8.68% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -2.4%, Pretax Profit Margin comes in at -3.58%, and Net Profit Margin reading is -3.58%. To continue investigating profitability, this company’s Return on Assets is posted at -1.84, Equity is 2.19 and Total Capital is -4.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Plus Therapeutics Inc [NASDAQ:PSTV] is 1.20. On the other hand, the Quick Ratio is 1.20, and the Cash Ratio is 0.31. Considering the valuation of this stock, the price to sales ratio is 12.69, the price to book ratio is 20.66.
Transactions by insiders
Recent insider trading involved Lenk Robert P, Director, that happened on Aug 22 ’25 when 0.11 million shares were purchased. Director, Petersen Greg completed a deal on May 15 ’25 to buy 36666.0 shares.
